Loading
MiNK Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 16 Oct 2023.
MiNK Therapeutics, Inc.: what insiders have been doing
Every trade that managers of MiNK Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. 8 insiders have disclosed 17 filings since 18 October 2025.
All open-market trades in the period are sales: 3 sales worth €71k, by 2 insiders, with no purchase on record. Buell Jennifer filed the largest sale, €65k, on 14 October 2026, which represents 0.14% of the company's market value.
With 17 filings in twelve months, the company is quieter than the median of 19 filings across the 5,812 companies we follow on the same exchange. Our records for MiNK Therapeutics, Inc. go back to 2021, with 9 purchases and 4 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of -12.5 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
97
Thresholds
n/a
Buy Volume
€15M
9 ops. · all time
Sell Volume
€156,809
4 ops. · all time
Who traded when
BuySaleBarbara Ryan2 sales
Jennifer Buell1 sale
Since the insiders bought
- -38.9%Entry US$11.30 · Close at T+365 US$6.90
- -40.4%Entry US$15.80 · Close at T+365 US$9.41
- +27.5%Entry US$13.80 · Close at T+365 US$17.60
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate MiNK Therapeutics, Inc. Strong Buy (bullish), based on 2 analysts. Average price target: US$39.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$10.23
Analyst consensus
2 analystsStrong buy
US$35.00Target US$39.00(+281%)US$43.00
Income statement
EBITDA-US$12.3M
Net income-US$12.5M0.0% margin
Valuation
PER (forward)-5.2x
Beta0.47
Balance sheet & cash
Market capUS$52.2M
Total debtUS$5.2M
Free Cash Flow-US$5.9M
Profitability & ownership
ROA-123.8%
% insiders59.4%
% institutions4.0%
Last declaration on 14 October 2026
Declarations97 total
23,191 sharesCommon StockSEC:0001193125-26-421529:0
6,938 shares@ US$10.560.14% mcap5.3% of flowCommon StockSEC:0001193125-26-421529:1
6,938 shares@ US$10.56140.12% mcap5.6% of flowCOMMON STOCKSEC144:0001973379-26-000350
1,444 shares@ US$12.380.029% mcap5.5% of flowCommon StockSEC:0001193125-26-253468:1
1,640 shares@ US$10.905.4% of flowCommon StockSEC:0001193125-26-253468:0
1,313 shares@ US$12.380.026% mcap5.7% of flowCommon StockSEC:0001193125-26-253466:1
1,491 shares@ US$10.905.6% of flowCommon StockSEC:0001193125-26-253466:0
200 shares@ US$10.17250.7% of flowCommon StockSEC:0001193125-26-102581:0
400 shares@ US$10.85831.5% of flowCommon StockSEC:0001193125-26-091707:0
10,024 shares@ US$11.120.18% mcap8.6% of flowCommon StockSEC:0001193125-26-012914:0
31,474 shares@ US$11.1227.0% of flowCommon StockSEC:0001193125-26-004799:0
1,612 shares@ US$11.095.5% of flowCommon StockSEC:0001193125-25-306681:0
1,466 shares@ US$11.095.7% of flowCommon StockSEC:0001193125-25-306680:0
1,128 shares@ US$11.09100.0% of flowCommon StockSEC:0001193125-25-306679:0
1,601 shares@ US$11.096.1% of flowCommon StockSEC:0001193125-25-306678:0
1,218 shares@ US$11.0920.6% of flowCommon StockSEC:0001193125-25-306676:0
1,263 shares@ US$11.095.9% of flowCommon StockSEC:0001193125-25-306675:0
5,351 shares@ US$15.360.13% mcap6.4% of flowCommon StockSEC:0001193125-25-230098:0
18,229 shares@ US$15.3621.7% of flowCommon StockSEC:0001193125-25-201376:0
1,173 shares@ US$13.865.7% of flowCommon StockSEC:0000950170-25-112882:0
1,011 shares@ US$13.865.9% of flowCommon StockSEC:0001193125-25-195095:0
975 shares@ US$13.8620.6% of flowCommon StockSEC:0001193125-25-195091:0
1,281 shares@ US$13.866.0% of flowCommon StockSEC:0001193125-25-195090:0
1,290 shares@ US$13.865.5% of flowCommon StockSEC:0000950170-25-112884:0
1,883 shares@ US$7.1720.9% of flowCommon StockSEC:0000950170-25-081609:0
25 of 97 declarations
About MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. (ticker INKT) is a U.S.-listed biotechnology company trading on the NASDAQ market in the United States, with principal executive offices in New York City. For investors, MiNK is a clinical-stage biotech focused on next-generation cell therapy, offering a high-risk, high-upside profile typical of early pipeline companies. The company was originally incorporated in 2017 as AgenTus Biosciences and later changed its name to MiNK Therapeutics in June 2021. It has strong historical ties to Agenus and has built its strategy around a proprietary allogeneic invariant natural killer T-cell (iNKT) platform designed for off-the-shelf use, avoiding the patient-specific manufacturing burden associated with many autologous cell therapies.
MiNK’s core business is the discovery, development, manufacturing, and potential commercialization of iNKT-based therapies aimed at modulating immune function in oncology and immune-mediated diseases. Its lead asset, agenT-797, is a cryopreserved allogeneic iNKT cell therapy being studied across multiple settings, including solid tumors, graft-versus-host disease (GvHD), and severe inflammatory lung disease such as acute respiratory distress syndrome (ARDS). The company has also described a pipeline of next-generation engineered iNKT programs, including CAR-iNKT approaches and antigen-targeted constructs, alongside external collaborations intended to broaden the platform into pediatric cancers and additional unmet-need indications.
Read moreShow less
From a competitive standpoint, MiNK seeks differentiation through three main attributes: an allogeneic, scalable platform; a broader immune-restoration thesis beyond oncology alone; and in-house manufacturing capabilities intended to improve reproducibility and support clinical execution. This positions the company differently from more conventional CAR-T developers, which often rely on individualized workflows that can be more complex and expensive. However, MiNK remains early-stage, meaning its investment case depends heavily on clinical validation, partner funding, and careful capital allocation.
During 2025 and into 2026, MiNK reported a steady flow of clinical and strategic updates, including Phase 2 progress for agenT-797 in checkpoint-refractory gastroesophageal cancer, publications and conference presentations in ARDS, expansion work in idiopathic pulmonary fibrosis (IPF), and a collaboration with C-Further to advance a PRAME-targeted iNKT program in pediatric oncology. These developments reinforce the company’s catalyst-driven profile, but also underscore that it remains a speculative NASDAQ biotech whose valuation will be shaped primarily by clinical readouts and execution rather than near-term commercial revenue.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
